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SUMMARY   (322 of 300 words) 38 
BACKGROUND: Previous randomised renal denervation studies failed to show consistent efficacy 39 
benefit in reducing blood pressure (BP).  40 
METHODS: SPYRAL HTN-OFF MED is a multicentre, international, single-blind, randomised, sham-41 
controlled, proof of concept trial (clinicaltrials.gov: NCT02439749). The objective was to evaluate the 42 
effect of renal denervation on BP in the absence of anti-hypertensive medications. Patients were enrolled 43 
at 21 centres in the USA, Europe, Japan and Australia. Eligible patients were drug naïve or discontinued 44 
their anti-hypertensive medications. Patients with an office systolic BP (SBP) ≥150 mmHg and <180 45 
mmHg, a diastolic BP (DBP) ≥90 mmHg and a 24-hour ambulatory SBP ≥140 mmHg and <170 mmHg at 46 
second screening underwent renal angiography and were randomised to renal denervation or sham 47 
control. Patients, caregivers, and those assessing BP were blinded to randomisation assignments. Changes 48 
in office and 24-hour BP at three months were compared between groups. Drug surveillance was 49 
employed to ensure patient compliance with medication withdrawalabsencse. Safety events were assessed 50 
through three months.   51 
FINDINGS: Eighty patients were randomiszed and followed through three months. Office and 24-hour 52 
ambulatory BP decreased significantly from baseline to three months in the renal denervation group 53 
(n=38); 24-hour SBP (-5·5 mmHg [-9·1, -2·0]), 24-hour DBP (-4·8 mmHg [-7·0, -2·6]), office SBP (-54 
10·0 mmHg [-15·1, -4·9]), and office DBP (-5·3 mmHg [-7·8, -2·7]).   There were no significant changes 55 
in the sham-control group (n=42); 24-hour SBP (-0·5 mmHg [-3·9, 2·9]), 24-hour DBP (-0·4 mmHg [-56 
2·2, 1·4]), office SBP (-2·3 mmHg [-6·1, 1·6]), and office DBP (-0·3 mmHg [-2·9, 2·2]).  The difference 57 
between groups favoured renal denervation for both office and 24-hour three-month change from 58 
baseline; 24-hour SBP (-5·0 mmHg [-9·9, -0·2]), 24-hour DBP (-4·4 mmHg [-7·2, -1·6]), office SBP (-59 
7·7 mmHg [-14·0, -1·5]) and office DBP (-4·9 [-8·5, -1·4]). Baseline-adjusted analysis gave very similar 60 
findings. There were no major adverse events in either group.  61 
4 
 
INTERPRETATION: Results from SPYRAL HTN-OFF MED provide biologic proof of principle for 62 
the BP lowering efficacy of renal denervation.  63 
FUNDING: Medtronic.  64 
  65 
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INTRODUCTION 66 
While the ability of renal denervation to decrease renal and systemic sympathetic tone was established by 67 
Esler et al1 and early clinical trials were promising2,3 , The encouraging results reported from the 68 
SYMPLICITY HTN-1 and HTN-2 trials1,2 led to substantial interest in percutaneous renal denervation as 69 
a potential device related non-pharmacological method to treat hypertension.  However, despite meeting 70 
its safety endpoint, the randomised, blinded, sham-controlled SYMPLICITY HTN-3 trial failed to 71 
demonstrate a statistically significant blood pressure lowering effect of renal denervation when compared 72 
with sham treatment.4 Post-hoc sub-analyses suggested postulated that variance in medication adherence, 73 
incomplete renal denervation of the renal arteries and the inclusion of patients with isolated systolic 74 
hypertension might have contributed to the surprisingly absence of an observable blood pressure 75 
reduction.5 Hence, the SPYRAL HTN-OFF MED was initiated to demonstrate that renal denervation 76 
could indeed impact blood pressure in a blinded, sham-controlled study. A new proof of concept trial was 77 
warranted due to dramatic trial design differences from previous studies.  These differences included the 78 
unknown impact on BPblood pressure reduction due to a different population (not “treatment resistant”), 79 
unknown impact on blood pressureBP reduction of a new procedure, and unknown impact on the 80 
variability of what had previously been a secondary endpoint but was now the main focus of measurement 81 
, namely 24-hour ambulatory blood pressure monitoring (ABPM). Since the actual blood pressure 82 
reduction relative to sham could not be predicted, a study of 120 evaluable patients randomised 1:1 was 83 
designed to demonstrate a clinically meaningful signal focused on ABPM.  84 
 Given the uncertainty of both the blood pressure reduction and standard deviation, analyses were pre-85 
specified at 40, 60, 80, and/or 100 subjects followed to three months so that if a clinically meaningful 86 
reduction was observed there could be rapid advancement to design and initiation of a powered, pivotal 87 
study.  We present here the primary three-month analysis of  the 80 subjects enrolled in the SPYRAL 88 
HTN-OFF MED trial. 89 
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 90 
METHODS 91 
Trial design and patients 92 
The design of the multicentre, international, single-blind, randomised, sham-controlled SPYRAL HTN-93 
OFF MED proof of concept trial has been described previously and is illustrated in appendix Figure S1.68 94 
Briefly, we enrolled patients 20 to 80 years old with mild to moderate hypertension, defined as office 95 
systolic blood pressure (SBP) ≥150 and <180 mmHg, office diastolic blood pressure (DBP) ≥90 mmHg, 96 
and a mean 24-hour ambulatory SBP ≥140 and <170 mmHg. Patients were enrolled at 21 centres: ten in 97 
the USA, four in Germany, two in Japan, two in the United Kingdom, one in Australia, one in Austria, 98 
and one in Greece. The trial complied with the Declaration of Helsinki, all local ethics committees 99 
approved the research protocol and written informed consent was obtained from all patients. The trial is 100 
registered at www.clinicaltrials.gov as NCT02439749. 101 
 102 
Screening and randomisation 103 
Randomisation to renal denervation or sham procedure was stratified by trial centre at a 1:1 ratio, using 104 
block randomisation with a block size of four. Randomisation was performed by ICON plc using SAS-105 
based software to generate the lists of randomisation codes. Participants were assigned to interventions 106 
through ICON’s website. Prior to randomisation, patients were required to be off all anti-hypertensive 107 
medications (Figure S1).68 An initial screening visit was conducted to verify initial eligibility criteria and 108 
initiate medication washout, if needed.   109 
After a three- to four-week period of medication washout, screening visit two confirmed patients’ 110 
eligibility for randomisation. Absence of anti-hypertensive medication usage was evaluated using tandem 111 
high performance liquid chromatography and mass spectroscopy of urine and plasma by an independent 112 
laboratory.79  Office blood pressure and heart rate measurements were obtained using an automatic blood 113 
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pressure monitor (Omron, see appendix), and patients whose office blood pressure remained within range 114 
(SBP ≥150 mmHg and <180 mmHg and DBP ≥90 mmHg) underwent 24-hour ambulatory blood pressure 115 
monitoring (ABPM; Mobil-O-Graph; I.E.M GmbH, Stolberg, Germany).  Blood pressure was measured 116 
every 30 minutes and a minimum of 21 daytime (7:00 to 21:59) and 12 night-time (22:00 to 6:59) 117 
measurements were required for inclusion in the analysis.  Patients had one opportunity to repeat ABPM 118 
data collection if they failed to record 21 daytime and 12 night-time readings, or the average 24-hour SBP 119 
was between 135-140 or 170-175 mmHg.  Mean 24-hour heart rate was also determined from the ABPM 120 
record as the average of all heart rates measured during the cuff pressure measurement cycle. 121 
Patients who satisfied all inclusion and exclusion criteria at the second screening visit were scheduled for 122 
renal angiogram and, if anatomical suitability was confirmed, proceeded to randomisation.  123 
Procedure 124 
The Symplicity SpyralTM multielectrode catheter (Medtronic, Galway, Ireland), and the Symplicity G3TM 125 
generator were used to provide radiofrequency ablation treatments. The four electrodes on the catheter are 126 
positioned to apply radiofrequency energy circumferentially in all four quadrants of the renal artery and 127 
branch vessels (Figure 1). All proceduralists had prior renal denervation experience and all cases were 128 
proctored based on detailed pre-specified treatment plans including a standardized approach to all 129 
accessible renal arterial vessels, including branch vessels and accessory arteries having a diameter of 130 
greater than three and less than eight mm.  To minimize procedural variability, the number of 131 
proceduralists was restricted to one per trial centre.   132 
In the control group, the sham procedure consisted of only a renal angiogram. Patients were also required 133 
to remain on the procedure table for at least 20 minutes post-angiogram to help prevent possible 134 
unblinding of randomisation allocation.  135 
 136 
Follow-up 137 
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Patients’ blood pressure was assessed at two-week intervals post-randomisation to ensure safety.  If a 138 
patient’s SBP surpassed the pre-specified escape criteria threshold (≥180 mmHg), and this was confirmed 139 
by repeated measurement within 72 hours, they could receive anti-hypertensive drug therapy at the 140 
discretion of the investigator. Otherwise, patients remained off anti-hypertensive medications post-141 
randomisation until follow-up at three months, when a prespecified drug titration protocol was initiated if 142 
SBP was greater than 140 mmHg. 143 
 144 
Maintenance of blinding  145 
Trial patients were not informed of their randomisation assignments and were blinded during the renal 146 
angiogram by a combination of conscious sedation, sensory isolation (blindfolding and music), and lack 147 
of familiarity to the procedural details and duration of the angiogram (i.e., patients were not expected to 148 
know the difference between the renal angiography procedure alone and the renal angiography and 149 
denervation procedure).  The proceduralist performing the angiogram and designated trial staff were 150 
blinded to the randomisation assignment until the angiography was completed and inclusion/exclusion 151 
criteria were confirmed.  Blinded trial staff conducted all trial follow-up visits and the patient’s 152 
referring/managing physicians were not informed of a patient’s treatment assignment. Per protocol, 153 
blinding of patients and BP assessors was maintained to 12 months post-randomisation. Patients were 154 
asked to guess which randomisation group they were in at discharge and three months to evaluate the 155 
strength of the blinding procedures.  156 
 157 
Efficacy endpoints 158 
The primary efficacy endpoint of blood pressure reduction based on ABPM measurements was assessed 159 
at three months, judged to be an acceptable amount of time for patients to withhold their anti-hypertensive 160 
medications and to observe a decrease in blood pressure. The change from baseline (blood pressure 161 
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measured at screening visit two) in SBP and DBP measurements obtained in-office and with 24-hour 162 
ABPM was assessed for the renal denervation and sham control groups at three-months post 163 
randomisation. The three-month change in BP measurements were then compared between the two 164 
treatment groups in order to assess if the ABPM sham-control subtracted SBP and the corresponding 165 
standard deviation was sufficient to justify design of a larger, powered pivotal trial. Continued absence of 166 
anti-hypertensive medication usage was assessed by urine and plasma sampling at baseline and at three 167 
months. Plasma samples were also analysed for sodium, potassium, renin activity, aldosterone, serum 168 
creatinine, and other relevant laboratory values. Estimated glomerular filtration rate (eGFR) was 169 
calculated using the four variable Modification of Diet in Renal Disease (MDRD) Formula or the local 170 
Japanese criteria for patients enrolled in Japan.810  171 
 172 
Safety endpoints 173 
Safety endpoints collected at three months included all-cause mortality, end-stage renal disease, any 174 
significant embolic event resulting in end-organ damage, hospitalization for hypertensive crises not 175 
related to medication nonadherence, new myocardial infarction, new stroke, renal artery re-intervention, 176 
major bleeding, major vascular complications and increase in serum creatinine >50% from screening 177 
assessment. End-stage renal disease is defined as two or more eGFR measurements <15 mL/min/1·73 m2 178 
at least 21 days apart and requiring dialysis.  179 
 180 
Statistical analysis 181 
The current proof-of-concept trial was designed in collaboration with the FDA and influenced by 182 
recommendations in the 2014 Scientific Statement by the American Society of Hypertension9  which 183 
suggested a Phase Two- type trial in a small group of patients. To conduct a properly powered 184 
10 
 
randomized trial suming a 5 mmHg SBP reduction with a stndard eviation of 12, itwas detrmined that 246 patients would be rquired. Because SYMPLICITY HTN-3 di not met iseficacy endpoint, iwas gred to proced with a smaler prof of concept rial that would minimize xposure of patients o the more invasive interventional procedure yet provide suficent evidence to move forward with a lrger, powerd trial. The protcol alowed up to 120 patients o be randomised with prospectively planed interim analyse 185 
after 40, 60,  and 80 and/or 100 patients completed three-month follow up, respectively. The purpose of each 186 
interim analysis was to determine if there was an adequate treatment effect with a reduction in variability 187 
of the blood pressure measurements. As a trial to inform further studies, results of the present proof of concept rial were reported when a treatment efect was observed with confidence suficient o alow design of a pivotal trial with confidencedesign. Al patients enroled 188 
after this decision point are planned to be included in the pivotal dataset, as discussed with the FDA, and 189 
thus this report represents the primary results of the SPYRAL HTN-OFF MED trial.  190 
There are no powered endpoints in the trial. To conduct a properly powered randomised trial assuming a 5 191 
mmHg SBP reduction with a standard deviation of 12, it was determined that 246 patients would be 192 
required. Considering the failure of SYMPLICITY HTN-3 it was agreed to proceed with a smaller proof 193 
of concept trial that would minimize exposure of patients to an interventional procedure and provide 194 
sufficient evidence to move forward with a larger, powered trial. Statistical analyses were performed 195 
based on the intention-to-treat principle. A modified intention-to-treat cohort excluded patients who met 196 
escape criteria (SBP ≥180 mmHg). For patients meeting escape criteria, the last observation was carried 197 
forward for three-month blood pressure assessment. A per-protocol analysis was also performed which 198 
excluded patients meeting escape criteria, who had antihypertensive medications measured in urine or 199 
serum, and who had at least one non-standardized blood pressure assessment. To adjust for baseline blood 200 
pressure measurements, Analysis of Covariance (ANCOVA) was employed as an additional analysis of 201 
blood pressure changes. 202 
Means and standard deviations of continuous variables are presented per treatment group. Between group 203 
differences and differences from baseline to the three-month follow-up assessment were tested with the 204 
use of unpaired and paired t-tests, respectively. For categorical variables, counts and percentages are 205 
presented per treatment group; values were tested with the use of the exact test for binary variables and 206 
the chi-square test for multilevel categorical variables. All reported subgroup analyses were prespecified.  207 
Commented [FM[1]: We have 90% power with 246 
patients under these assumptions. 
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Correlation of office with 24-hour SBP measurements per patient was analysed using regression methods. 208 
A blinding index, based on responses to a questionnaire, was calculated at hospital discharge and at three 209 
months to verify the effectiveness of blinding.101  210 
Role of the funding source 211 
The SPYRAL HTN-OFF MED trial was funded by Medtronic (Santa Rosa, CA, USA). The trial 212 
executive committee designed the protocol in conjunction with the funder. The funder was responsible for 213 
selection of clinical sites, in collaboration with the executive committee, as well as collection, monitoring 214 
and analysis of the data. The manuscript was written by the lead author with substantial contributions 215 
from the executive committee and co-authors. The funder assisted in figure and table generation, copy 216 
editing and formatting. The authors had unrestricted access to the data and had full responsibility for the 217 
decision to submit for publication.   218 
 219 
RESULTS 220 
The current analysis presents results from the first 80 patients randomised (38 to renal denervation and 42 221 
to sham) from a total of 353 patients enrolled and screened between June 2015 and May 2017 (Figure 2). 222 
At the interim analysis of 80 patients, a reduction in BP, as well as in variability of 24-hour BP 223 
measurements was seen; all patients randomised after these 80 patients will contribute to the pivotal 224 
dataset. There were no significant differences in baseline clinical characteristics, weight, heart rate, office, 225 
or mean 24-hour SBP and DBP between the renal denervation and sham control groups although there 226 
were more current smokers in the sham-control group than the renal denervation group (23.8% vs 10.5%) 227 
(Table 1).  228 
 229 
All patients underwent aortography and selective renal angiography. Angiographic documentation of 230 
catheter position for the renal denervation group was required.  During the procedure, a mean of 251·0 ± 231 
99·4 cc of contrast was used in the renal denervation group and 83·3 ± 38·5 cc in the sham control group. 232 
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For the renal denervation group, on a patient basis, proceduralists performed an average of 43·8 ± 13·1 233 
total ablations, and treated an average of 2·2 main arteries (17·9 ± 10·5 ablations) and 5·2 branch vessels 234 
(25·9 ± 12·8 ablations).  235 
The blinding index was 0·65 (0·56, 0·75) at discharge and 0·59 (0·49, 0·70) at three months, indicating 236 
proper blinding.101  237 
 238 
Drug testing was performed at baseline and three months to identify whether patients were taking any 239 
anti-hypertensive medications. At baseline, 92·1% (35/38) of renal denervation patients and 88·1% 240 
(37/42) of sham control patients had no evidence of anti-hypertensive medication use (p=0·72). At three 241 
months, for available data, 94·3% (33/35) of renal denervation and 92·7% (38/41) of sham control 242 
patients had no anti-hypertensive medications detected (p>0·99). Overall compliance with the 243 
requirement to be off antihypertensive medications at baseline and 3 months was 85.5%.  Of the six 244 
patients who met escape criteria following randomiszation, three had drugs measured at three months, 245 
drugs were not detected in two patients, and one patient did not undergo drug testing.  There were no 246 
significant differences in baseline laboratory values or in the three-month change in values between the 247 
renal denervation and sham control groups (Appendix, Table S2).   248 
 249 
The three month SBP and DBP change from baseline for both 24-hour ambulatory and office 250 
measurements in the renal denervation and sham control groups is displayed in Figure 3, and Table 2.  251 
The change in blood pressure was greater at three months for the renal denervation group vs. sham control 252 
for 24-hour ambulatory SBP (difference -5·0 mmHg [-9·9, -0·2], p=0·04) as well as office SBP 253 
(difference -7·7 mmHg [-14·0, -1·5], p=0·02). The same was documented for 24-hour DBP (difference -254 
4·4 mmHg [-7·2, -1·6] p=0·002) and office DBP (difference -4·9 mmHg [-8·5, -1·4] p=0·008). 255 
Comparison of office and 24-hour blood pressure measurements at baseline and three months for renal 256 
denervation and sham control groups are included in appendix Table S3.  257 
 258 
13 
 
Comparison of three-month change, adjusted for baseline measures using ANCOVA, provide similar 259 
results with a 24-hour SBP between group difference of -4.6 mmHg [-9·2, 0·1], p=0·053 and 24-hour 260 
DBP between group difference of -4·3 mmHg [-7·1, -1·5], p=0·003.  Office SBP difference was -7·1 [-261 
13·2, -1·1], p=0·021 and office DBP difference was -5·0 mmHg [-8·6, -1·4], p=0·008 (Table 2).  Results 262 
were consistent using unadjusted and baseline-adjusted analysis for the modified ITT and per-protocol 263 
populations (Appendix Table S4). 264 
 265 
Individual patient responses to renal denervation or sham procedure via office and 24-hour BP 266 
measurements are illustrated in Figure 4.  As expected, the three-month change in blood pressure after 267 
renal denervation was correlated between 24-hour and office measurements (r=0·41, p=0·01) but this 268 
correlation was not observed in the sham control group (r=0·06, p=0·72) (Appendix Figure S2).    269 
 270 
There were no major procedural or clinical safety events in either the renal denervation or sham control 271 
groups out to three months (Appendix Table S5). Specifically, there were no cases of death or 272 
occurrences of myocardial infarction, stroke, major bleeding, serum creatinine elevation >50%, 273 
significant embolic events, vascular complications, renal artery re-intervention, new or worsening renal 274 
failure, or hypertensive emergency/crisis.  275 
 276 
 277 
DISCUSSION 278 
This novel trial differs substantially from previous renal denervation trials in the hypertensive population 279 
enrolled, the renal denervation technique employed, and the absence of concomitant anti-hypertensive 280 
medications. To our knowledge, this is the first rigorously conducted sham controlled clinical trial to 281 
assess BP reduction in hypertensive patients in the absence of anti-hypertensive medications. These data 282 
provide the biologic proof of principle that renal denervation as performed in this trial lowers blood 283 
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pressure in untreated hypertensive patients and supports the prior data from Esler et al about the 284 
correlation of reduction in sympathetic tone and blood pressure reduction.1 While not powered for 285 
efficacy endpoints,  a substantial difference in both office and mean 24-hour ambulatory SBP and DBP 286 
change was observed between the renal denervation and sham control groups at three months. In addition, 287 
the renal denervation group had significant changes from baseline to three months in office and mean 24-288 
hour ambulatory blood pressures. Of note, the sham control group had a small, non-significant change in 289 
blood pressure.  290 
 291 
A new proof of concept trial was warranted due to substantial trial design differences from the previous 292 
SYMPLICITY HTN-1 proof of concept trial112 based on key learnings from subsequent clinical 293 
trials. The current trial design was influenced by several key learnings. These included recent advances in 294 
our understanding of renal nerve anatomy12, the potential impact of concurrent drug therapy54,13, the 295 
importance of operator experience and an individual procedural treatment plan14, and the biological 296 
difference between combined systolic-diastolic hypertension and isolated systolic hypertension (office 297 
DBP <90 mmHg with a SBP ≥140 mmHg).155  Most prior renal denervation trials enrolled patients with 298 
resistant1,3,42,3,15 or moderate hypertension13,16 while patients continued their anti-hypertensive regimen 299 
without excluding isolated systolic hypertension patients. Unlike earlier SYMPLICITY trials that utilized 300 
a single electrode renal denervation catheter in main renal arteries exclusively, the current trial utilized a 301 
multi-electrode catheter that delivered up to four simultaneous, radiofrequency ablations in a helical 302 
pattern and included branch vessel treatment. Further clinical studies are needed to evaluate the effect of 303 
different catheters and treatment protocols on efficacy of BP reduction.  304 
Elimination of anti-hypertensive medications as a confounding factor in the evaluation of efficacy of renal 305 
denervation was important as adherence to anti-hypertensive medications has been well documented to be 306 
unpredictable over time in hypertension clinical studies17,18 and specifically in renal denervation clinical 307 
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studies.19,20  Several hypertension studies found an association between a higher number of detected anti-308 
hypertensive medications and lower blood pressure in patients,12,20−23 underscoring the importance of 309 
objective measurement of medication adherence in an interventional therapy trial. The standard deviations 310 
for blood pressure change were notably tighter in this compared tothan in previous trials and may be 311 
attributed to removing drug adherence confounding of blood pressure measurement, to patient selection, 312 
as well as to proctoring to ensure consistency in performance of renal denervation and the addition of 313 
branch vessel treatment.  Moreover, in the SPYRAL HTN-OFF MED trial, despite known drug 314 
surveillance, compliance with the requirement to remain off antihypertensive drugs through three months 315 
was 85·5%, illustrating the value of drug surveillance.  316 
Results from the current trial are supported by data from several important trials that suggest an effect of 317 
renal denervation in treating hypertension. Symplicity HTN-1, an open-label proof-of-principle study, 318 
was among the first to report a significant BP reductions in patients with resistant hypertension, that were 319 
evident by 1 month and sustained through three years.2,11 The Renal Denervation for Hypertension 320 
(DENERHTN) prospective, open-label, randomised, controlled trial reported a significant difference in 321 
reduction in daytime ambulatory SBP after renal denervation plus antihypertensive medication compared 322 
to a control medication alone group.24 A second recent retrospective, non-randomised analysis of renal 323 
denervation in a non-medicated hypertensive population documented a reduction in 24-hour SBP of -5·7 324 
mmHg after renal denervation treatment.25  325 
The choice of 24-hour SBP as the primary endpoint resulted from consensus that it is less prone to bias,  326 
and, due to the multiple measurements, not only better reflects a patient’s blood pressure but also 327 
demonstrates less variability of measurement;9,29-31 for these reasons it was the endpoint recommended by 328 
regulatory authorities including the FDA.  There was a significant correlation between ambulatory and 329 
office blood pressure changes in patients after renal denervation. This observation suggests that either 330 
measure may be appropriate for future clinical trials when office BP measurements are blinded. In line 331 
with expectations, a numerically smaller decrease was observed in the 24-hour ambulatory measurements. 332 
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The minimal blood pressure reductions in the sham control group did not show a similar relationship 333 
supporting the reduction of blood pressure specifically in response to renal denervation rather than other 334 
confounding factors.  335 
The magnitude of the presently observed SBP reductions in the renal denervation arm, -10·0 mmHg for 336 
office (p<0·001) and -5·5 mmHg for 24-hour ABPM (p=0·003), represent clinically meaningful 337 
reductions in blood pressure. Blood pressure reductions of similar magnitudes have been associated with 338 
reduced rates of cardiovascular death, coronary death and stroke.32-3429−31 For example, a recent meta-339 
analysis predicts an approximate 20% reduction in relative risk for cardiovascular events with the 340 
presently observed 7.7 mmHg sham-adjusted reduction in office SBP.330  Likewise, the observed 341 
reduction in 24-hour ambulatory blood pressure is also associated with relative risk reductions and meets 342 
the criteria recommended by an expert panel.27,29,35,366,32−34 It is noteworthy that unclear why there is a 343 
greater reduction in DBP after renal denervation in our trial. It is possible that this is related to the 344 
mechanism of action of renal denervation related to vascular tone or may be due to the exclusion of 345 
patients with isolated hypertension, but this is only speculation at this point. 346 
Changes in renal denervation procedural requirements in SPYRAL HTN-OFF MED may have also 347 
contributed to the reduction in blood pressure observed in the treatment group. Based on more recent 348 
preclinical and clinical data a greater number of ablations were delivered in a circumferential pattern 349 
within the main artery, renal artery branches and accessory arteries of greater than three to less than eight 350 
mm in diameter, whereas in previous studies only the main renal artery was treated, the total number of 351 
ablations were fewer, ablations were not applied in a circumferential pattern and accessory renal arteries 352 
were not treated.5,8,14 In SPYRAL HTN-OFF MED, 17·9 ± 10·5 ablations were attempted in the main 353 
renal arteries and 25·9 ± 12·8 ablations in branch vessels as compared with 11·2 ± 2·8 ablation attempts 354 
and no branch treatments in SYMPLICITY HTN-3. Nevertheless, not all patients responded to renal 355 
denervation treatment in this trial, which could be explained by variations in the degree of renal nerve 356 
innervation between patients,12 or differences in the underlying pathophysiology.  357 
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There are several limitations to our trial. As a feasibility proof of concept trial, it was designed with a small sample 358 
size, and was not powered for statistical significance given the uncertainty of the placebo-subtracted 359 
blood pressure reduction and of the standard deviation of these measurements. Some patients had anti-360 
hypertensive medications measured in their urine or serum, met escape criteria, or had blood pressure 361 
measured in a non-standardized manner; however, the findings were consistent in the primary intention to 362 
treat analysis as well as the modified intention to treat and per protocol analyses when these patients were 363 
excluded from analysis (Appendix Table S3). The three-month follow-up was relatively short; however, a 364 
short off-med period was specified per-protocol for safety reasons. After three-months antihypertension 365 
medications could be titrated as needed and thus there was not a substantial cohort of truly off-med 366 
patients after this time point. While renal denervation was performed to achieve complete and 367 
comprehensive denervation of the kidneys, no practical methods to verify nerve destruction are currently 368 
available.  As previously described and similarly to trials of pharmacological therapies, not all 369 
participants experienced a blood pressure reduction post-renal denervation treatment.  Furthermore, the 370 
method employed in this trial may not be generalizable to other renal denervation technologies or other 371 
populations not studied.  372 
In conclusion, results from SPYRAL HTN-OFF MED provide biologic proof of principle for the efficacy 373 
of catheter based renal denervation to reduce blood pressure in hypertensive subjects not treated with 374 
antihypertensive medications. We demonstrated a clinically significant reduction in office and 24-hour 375 
ambulatory SBP and DBP at three months in mild to moderate hypertensive patients following renal 376 
denervation in the absence of anti-hypertensive medications that was not observed in the sham control 377 
group. There were no major safety events in either group despite lack of pharmacologic therapy from 378 
enrolment to three- month follow-up and a more aggressive renal denervation procedure that extended 379 
into renal artery branch vessels. The results of this trial will be useful in informingserve as the basis to 380 
inform on adesign of a  pivotal trial design.   381 
 382 
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Research in Context 440 
Evidence before this study  441 
Early uncontrolled and unblinded trials reported large reductions in blood pressure following renal 442 
denervation in patients with uncontrolled hypertension. However, the results of the randomised, sham-443 
controlled SYMPLICITY HTN-3 trial showed no statistically significant blood pressure lowering benefits 444 
over sham treatment although continued follow-up of patients from multiple studies has confirmed the 445 
safety of renal denervation. Subsequent post-hoc analyses of SYMPLICITY HTN-3 suggested that 446 
ablation of the renal nerves, patient non-adherence to anti-hypertensive medications and patient selection 447 
might have impacted these results.  Continued pre-clinical and clinical research provided evidence for the 448 
importance of circumferential ablations in both the main renal arteries and vessel branches.   449 
Added value of this study  450 
The SPYRAL HTN-OFF MED trial was designed to evaluate the effectfeasibility of renal denervation to 451 
influence blood pressure in non-medicated patients with mild to moderate hypertension. While not 452 
powered for efficacy endpoints, patients randomised to renal denervation experienced significant 453 
reductions in office and 24-hour ambulatory blood pressure compared to much smaller, non-significant 454 
blood pressure reductions in the sham control patients. These results provide the biologic proof of concept 455 
for the effect of renal denervation on blood pressure when performed by the described method.  456 
Implications of all the available evidence  457 
The results of this proof of conceptfeasibility trial will inform the design of a larger pivotal trial that will 458 
be important to establish the role of renal denervation in the treatment of hypertension.  459 
 460 
  461 
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Table 1: Patient characteristics and blood pressure measurements at baseline.  558 
Characteristic* 
Mean±SD or % (N) 
Renal Denervation 
Group 
(N=38) 
Sham Procedure 
Group 
(N=42) 
Age (years) 55·8 ± 10·1 (38) 52·8 ± 11·5 (42) 
Male 68·4% (26/38) 73·8% (31/42) 
BMI (kg/m2) 29·8 ± 5·1 (38) 30·2 ± 5·1 (42) 
Race   
     White 26·3% (10/38) 23·8% (10/42) 
     Black/African American 13·2% (5/38) 11·9% (5/42) 
     Asian 7·9% (3/38) 7·1% (3/42) 
     Not reportable per local laws/regulations 52·6% (20/38) 57·1% (24/42) 
Diabetes (all type 2) 2·6% (1/38) 7·1% (3/42) 
Current smoker 10·5% (4/38) 23·8% (10/42) 
Obstructive sleep apnea 7·9% (3/38) 7·1% (3/42) 
Peripheral artery disease 2·6% (1/38) 0·0% (0/42) 
Coronary artery disease† 0·0% (0/38) 4·8% (2/42) 
Stroke and transient ischemic attack† 5·3% (2/38) 0·0% (0/42) 
Myocardial infarction/Acute coronary 
syndrome† 
0·0% (0/38) 2·4% (1/42) 
   
Office SBP (mm Hg) 162·0 ± 7·6 (38) 161·4 ± 6·4 (42) 
Office DBP (mm Hg) 99·9 ± 6·8 (38) 101·5 ± 7·5 (42) 
Mean 24-hour SBP (mm Hg) 153·4 ± 9·0 (37) 151·6 ± 7·4 (42) 
Mean 24-hour DBP (mm Hg) 99·1 ± 7·7 (37) 98·7 ± 8·2 (42) 
Office heart rate (bpm) 71.1 ± 11.0 (38) 73.4 ± 9.8 (42) 
24-hour heart rate (bpm) 72.3 ± 10.9 (37) 75.5 ± 11.5 (42) 
*All comparisons between renal denervation and sham control groups were non-significant.  559 
†These events occurred more than three months before randomiszation.  560 
BMI: Body mass index; SBP:  systolic blood pressure; DBP: diastolic blood pressure; bpm: beats per 561 
minute 562 
 563 
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Table 2: Blood pressure changes at three months in intent-to-treat (ITT) population. 95% confidence intervals and p-values are included for each 569 
comparison.    570 
BP Measure 
Renal Denervation Group Sham Control Group Mean Difference: 
Renal Denervation vs Sham Control 
Unadjusted1 
Baseline 
Adjusted2 
Unadjusted1 
Baseline 
Adjusted2 
Unadjusted3 
Baseline 
Adjusted4 
ITT Population 
 n=37 n=41  
3-Month Office 
SBP Change 
-10·0 [-15·1, -4·9] 
p=0.0004 
-9·7 [-14·1, -5·3] 
p<0·0001 
-2·3 [-6·1, 1·6] 
p=0·2381 
-2·5 [-6·7, 1·6] 
p=0·2273 
-7·7 [-14·0, -1·5] 
p=0·0155 
-7·1 [-13·2, -1·1] 
p=0·0212 
3-Month Office 
DBP Change 
-5·3 [-7·8, -2·7] 
p=0.0002 
-5·3 [-7·9, -2·7] 
p=0·0001 
-0·3 [-2·9, 2·2] 
p=0·8052 
-0·3 [-2·8, 2·2] 
p=0·8158 
-4·9 [-8·5, -1·4] 
p=0·0077 
-5·0 [-8·6, -1·4] 
p=0·0076 
              n=35                        n=34 n=36  
3-Month 24-Hour 
SBP Change 
-5·5 [-9·1, -2·0] 
p=0·0031 
-5·3 [-8·6, -2·0] 
p=0·0020 
-0·5 [-3·9, 2·9] 
p=0·7644 
-0·7 [-4·0, 2·5] 
p=0·6523 
-5·0 [-9·9, -0·2] 
p=0·0414 
-4·6 [-9·2, 0·1] 
p=0·0528 
3-Month 24-Hour 
DBP Change 
-4·8 [-7·0, -2·6] 
p<0·0001 
-4·8 [-6·8, -2·8] 
p<0·0001 
-0·4 [-2·2, 1·4] 
p=0·6448 
-0·5 [-2·4, 1·5] 
p=0·6433 
-4·4 [-7·2, -1·6] 
p=0·0024 
-4·3 [-7·1, -1·5] 
p=0·0028 
BP: blood pressure; DBP: diastolic blood pressure; ITT: Intention-to-treat; SBP: systolic blood pressure 571 
1 p-value from paired t-test 572 
2 BP change and p-value from Least Squares Means estimation in ANCOVA model 573 
3 p-value from unpaired t-test 574 
4 Treatment difference and p-value from ANCOVA model, adjusting for baseline BP 575 
 576 
 577 
 578 
  
Figure legends 579 
 580 
Figure 1: Angiographic images of multi-electrode denervation catheter applying circumferential ablations 581 
in renal arteries.  582 
 583 
Figure 2: Trial profile  584 
ITT: Intention-to-treat; mITT: modified intention-to-treat; PPP: per-protocol population 585 
 586 
Figure 3: Change at 3 months in office and ambulatory SBP and DBP for treatment and sham control 587 
patients using un-adjusted p-values. 588 
SBP: systolic blood pressure; DBP: diastolic blood pressure 589 
 590 
Figure 4: Changes at three months for individual patients in renal denervation and sham control groups 591 
for: 592 
A) 24-hour ambulatory SBP and DBP  593 
B) Office SBP and DBP 594 
 595 
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